Peak Bio (PKBO) Competitors $0.02 -0.05 (-67.86%) (As of 11/14/2024 09:01 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrends PKBO vs. MAAQ, BPTH, SONN, AKAN, SLRX, SRNE, PHIO, GLMD, DRMA, and BONShould you be buying Peak Bio stock or one of its competitors? The main competitors of Peak Bio include Mana Capital Acquisition (MAAQ), Bio-Path (BPTH), Sonnet BioTherapeutics (SONN), Akanda (AKAN), Salarius Pharmaceuticals (SLRX), Sorrento Therapeutics (SRNE), Phio Pharmaceuticals (PHIO), Galmed Pharmaceuticals (GLMD), Dermata Therapeutics (DRMA), and Bon Natural Life (BON). These companies are all part of the "pharmaceutical products" industry. Peak Bio vs. Mana Capital Acquisition Bio-Path Sonnet BioTherapeutics Akanda Salarius Pharmaceuticals Sorrento Therapeutics Phio Pharmaceuticals Galmed Pharmaceuticals Dermata Therapeutics Bon Natural Life Mana Capital Acquisition (NASDAQ:MAAQ) and Peak Bio (NASDAQ:PKBO) are both small-cap unclassified companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability, community ranking and earnings. Do institutionals & insiders hold more shares of MAAQ or PKBO? 68.4% of Mana Capital Acquisition shares are owned by institutional investors. 19.9% of Peak Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media refer more to MAAQ or PKBO? In the previous week, Peak Bio had 3 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 3 mentions for Peak Bio and 0 mentions for Mana Capital Acquisition. Mana Capital Acquisition's average media sentiment score of 0.00 beat Peak Bio's score of -0.01 indicating that Mana Capital Acquisition is being referred to more favorably in the media. Company Overall Sentiment Mana Capital Acquisition Neutral Peak Bio Neutral Which has preferable earnings & valuation, MAAQ or PKBO? Mana Capital Acquisition has higher earnings, but lower revenue than Peak Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMana Capital AcquisitionN/AN/AN/AN/AN/APeak Bio$370K1.41-$12.83M-$0.16-0.14 Is MAAQ or PKBO more profitable? Company Net Margins Return on Equity Return on Assets Mana Capital AcquisitionN/A N/A N/A Peak Bio N/A N/A -179.31% Does the MarketBeat Community prefer MAAQ or PKBO? Mana Capital Acquisition and Peak Bio both received 1 outperform votes by MarketBeat users. CompanyUnderperformOutperformMana Capital AcquisitionOutperform Votes1100.00% Underperform VotesNo VotesPeak BioOutperform Votes1100.00% Underperform VotesNo Votes SummaryMana Capital Acquisition and Peak Bio tied by winning 3 of the 6 factors compared between the two stocks. Ad Porter & CompanyThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly repeat itself with the AI frenzy. I urge you to watch it before you invest another cent. Again, to be clear, I’m no Chicken Little. Far from it. So go here now to read my new report The Big AI Die-Up… while you still can. Get Peak Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PKBO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PKBO vs. The Competition Export to ExcelMetricPeak BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$520,000.00$2.87B$5.07B$8.73BDividend YieldN/A1.83%7.49%4.06%P/E Ratio-0.1440.79128.1717.30Price / Sales1.41381.121,372.3693.65Price / CashN/A166.9237.1935.20Price / Book-0.034.036.415.88Net Income-$12.83M-$42.58M$115.57M$224.23M7 Day PerformanceN/A-12.44%-5.65%-0.18%1 Month PerformanceN/A-7.37%-4.49%2.91%1 Year PerformanceN/A23.28%28.70%25.38% Peak Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PKBOPeak BioN/A$0.02-67.9%N/A-71.8%$520,000.00$370,000.00-0.143Gap DownHigh Trading VolumeMAAQMana Capital AcquisitionN/A$0.26-3.8%N/A-74.5%$2.07MN/A0.001High Trading VolumeBPTHBio-Path3.1419 of 5 stars$0.81-10.0%N/A-92.3%$2.07MN/A0.0010Analyst ForecastGap UpSONNSonnet BioTherapeutics1.8627 of 5 stars$3.02+0.7%N/A+109.7%$2.06M$150,000.000.0012Trading HaltedAKANAkandaN/A$1.39-6.1%N/A-95.9%$1.98M$2.16M0.00110Gap DownSLRXSalarius Pharmaceuticals0.4169 of 5 stars$1.34-2.9%N/A-75.7%$1.93M$1.84M-0.1620SRNESorrento TherapeuticsN/A$0.00flatN/A-93.3%$1.93M$62.84M0.00800Analyst ForecastNews CoverageGap DownPHIOPhio Pharmaceuticals2.2077 of 5 stars$2.21-0.9%N/A-75.9%$1.90MN/A-0.208Gap UpGLMDGalmed Pharmaceuticals1.1946 of 5 stars$2.93-5.5%N/A-40.0%$1.89MN/A-0.1820Gap DownDRMADermata Therapeutics2.1974 of 5 stars$1.12-5.9%N/A-89.3%$1.69MN/A-0.078BONBon Natural LifeN/A$1.42+5.2%N/A-67.0%$1.67M$29.52M0.00100Gap Up Related Companies and Tools Related Companies MAAQ Competitors BPTH Competitors SONN Competitors AKAN Competitors SLRX Competitors SRNE Competitors PHIO Competitors GLMD Competitors DRMA Competitors BON Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PKBO) was last updated on 11/18/2024 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | SponsoredThe Stock Powering Musk’s AI Revolution—RevealedImagine being able to invest in Tesla, PayPal, or SpaceX before the world knew their potential. Today, you ...InvestorPlace | SponsoredTrump’s EPIC Stock Market RallyPutting HUGE gain chances in the hands of hardworking, patriotic Americans like YOU. In fact, according to ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Peak Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Peak Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PKBO with Qtrade Free PKBO Stock Alerts